Courtney M.W. Tygesson

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine and patient care through artificial intelligence, on its offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2030 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Cooley advised AIRO Group Holdings, a company specializing in advanced aerospace and defense technologies, on its $69 million initial public offering (IPO).

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its up to $75 million debt financing. Partner Addison Pierce led the Cooley team, which included Courtney Tygesson, Madison Jones, Margaret Barreto and Katie Lapidus.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.